5.56
4.51%
0.24
시간 외 거래:
5.56
전일 마감가:
$5.32
열려 있는:
$5.34
하루 거래량:
94,850
Relative Volume:
0.39
시가총액:
$314.81M
수익:
-
순이익/손실:
$-66.86M
주가수익비율:
-4.1493
EPS:
-1.34
순현금흐름:
$-58.82M
1주 성능:
+2.77%
1개월 성능:
+11.20%
6개월 성능:
+49.46%
1년 성능:
+153.88%
디자인 테라 Stock (DSGN) Company Profile
명칭
Design Therapeutics Inc
전화
858-293-4900
주소
6005 HIDDEN VALLEY ROAD, CARLSBAD
디자인 테라 Stock (DSGN) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2023-05-04 | 업그레이드 | Goldman | Sell → Neutral |
2022-06-10 | 개시 | Wedbush | Outperform |
2022-05-02 | 개시 | RBC Capital Mkts | Outperform |
2022-01-19 | 개시 | Goldman | Sell |
2021-04-20 | 개시 | Goldman | Neutral |
2021-04-20 | 개시 | Piper Sandler | Overweight |
2021-04-20 | 개시 | SVB Leerink | Outperform |
모두보기
디자인 테라 주식(DSGN)의 최신 뉴스
CARGO Therapeutics Announces ASH 2024 Abstract on CRG-023, - GlobeNewswire
Absci and Twist Bioscience Collaborate to Design Novel Antibody using Generative AI - Yahoo Finance
Karyopharm to Host Investor Event with Leading Myelofibrosis KOLs and Provide a Favorable Study Design Update on October 31, 2024 - Longview News-Journal
A new biotech, built around protein design, springs from David Baker’s lab - BioPharma Dive
Dr. Beyza Bulutoglu Celebrated for Dedication to the Field of Protein Engineering and Drug Discovery - 24-7 Press Release
Spinocerebellar Ataxias Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - Barchart
Seaport Therapeutics Secures $225M for New Kind of Depression Drug - MedCity News
Synthetic Nanoassemblies for Regulating Organelles: From Molecular Design to Precision Therapeutics - ACS Publications
Spinocerebellar Ataxias Pipeline Review 2024: Clinical Trials Update and Key Companies Involved by DelveInsight | Biogen Inc, BioXcel Corp, Celavie Biosciences, Ionis Pharma, Anima Biotech Inc - Barchart
Enhancing De Novo Drug Design across Multiple Therapeutic Targets with CVAE Generative Models - ACS Publications
When (DSGN) Moves Investors should Listen - Stock Traders Daily
OSE Immunotherapeutics Presents New “Cis-Demasking” Bispecific Technology for the Design of Cytokine Drugs with Improved Therapeutic Index - Yahoo Finance
ElevateBio Announces Advancements of its Proprietary Lipid Nanoparticle (LNP) Delivery Platform with Liver Targeting and De-Targeting Potential - ForexTV.com
Glycomic Therapeutics Market Innovations, Challenges, - openPR
Dimensional Fund Advisors LP Has $271,000 Stock Holdings in Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World
Marshall Wace LLP Buys New Shares in Security National Financial Co. (NASDAQ:SNFCA) - Defense World
Marshall Wace LLP Cuts Stock Holdings in ARC Document Solutions, Inc. (NYSE:ARC) - Defense World
Marshall Wace LLP Invests $81,000 in Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World
Marshall Wace LLP Reduces Holdings in TrueCar, Inc. (NASDAQ:TRUE) - Defense World
Squarepoint Ops LLC Has $294,000 Stock Holdings in Civeo Co. (NYSE:CVEO) - Defense World
Squarepoint Ops LLC Increases Stock Holdings in Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World
Squarepoint Ops LLC Lowers Stock Holdings in AerSale Co. (NASDAQ:ASLE) - Defense World
Cyrus Biotechnology Congratulates David Baker, 2024 Nobel Laureate in Chemistry and Cyrus Co-Founder - BioSpace
Tech News | American Press Technology News - Business Wire
Windtree Therapeutics Publishes SEISMiC Phase 2b Trial Design for Cardiac Treatment - MyChesCo
Windtree Announces Publication of Positive Istaroxime Phase 2b Study Trial Design - Yahoo Finance
Cubist Systematic Strategies LLC Grows Stock Holdings in Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World
Design Therapeutics (NASDAQ:DSGN) Is In A Good Position To Deliver On Growth Plans - Simply Wall St
Point72 Asset Management L.P. Buys 397,285 Shares of Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World
Point72 Asset Management L.P. Has $3.32 Million Holdings in Design Therapeutics, Inc. (NASDAQ:DSGN) - MarketBeat
Point72 Asset Management L.P. Raises Stock Holdings in Larimar Therapeutics, Inc. (NASDAQ:LRMR) - Defense World
Almitas Capital LLC Has $4.20 Million Stake in Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World
Almitas Capital LLC Purchases 227,180 Shares of Design Therapeutics, Inc. (NASDAQ:DSGN) - MarketBeat
Wall Street SWOT: Design Therapeutics stockInnovative approach in genetic disorder treatment - Investing.com
(DSGN) On The My Stocks Page - Stock Traders Daily
Pleasing Signs As A Number Of Insiders Buy Design Therapeutics Stock - Yahoo Finance
Gain Therapeutics To Host Virtual Webinar on Results From Phase 1 Study and Design of Upcoming - The Bakersfield Californian
Neurological diseases index falls; Sarepta and Intra-Cellular report gains - BioWorld Online
Septerna Marks Transition to a Clinical-Stage Company with Appointments of Industry Veterans in Key Drug Development Roles - Business Wire
Halozyme Therapeutics And 6 Other Stocks Have High Sales Growth And An Above 3% Return on Equity - Via News Agency
Zevra Therapeutics to Present Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at Sleep Europe 2024 - StockTitan
How to interpret Design Therapeutics Inc (DSGN)’s stock chart patterns - US Post News
Friedreich’s Ataxia Treatment Market Size in the 7MM will experience significant changes during the forecast period of 2024-2034, estimated DelveInsight - Barchart
Initial in vivo validation of novel cancer therapeutics using AI - Drug Target Review
Designer brands director sells $145,640 in company stock - Investing.com
Progressive Ataxia And Weakness Disorders Market Segments, Drivers, Restraints, And Trends For 2024-2033 - EIN News
Rocket Pharmaceuticals Maxes Out Recruitment in Pivotal Trial for Danon Disease Gene Therapy RP-A501 - CGTLive™
4DMT Highlights Robust and Durable Clinical Activity for 4D-150 and Design of 4FRONT Phase 3 Program at 4D-150 Wet AMD Development Day - Yahoo Finance
Designer Brands Inc’s latest rating changes from various analysts - Knox Daily
Short Interest in Dyne Therapeutics, Inc. (NASDAQ:DYN) Decreases By 6.9% - MarketBeat
MIRA Pharmaceuticals Advances Ketamir-2 Development Following Phase 1 Design Completion, Focusing on Early Clinical Efficacy Demonstration for Neuropathic Pain in 2025 - StockTitan
디자인 테라 (DSGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):